Patent ID: 8809617
Filing Date: 2014-08-19
Classification: A01K,A61K,C07K,C12Q,G01N

Abstract:
1. A high-throughput method of determining whether a test compound may be therapeutically effective in treating a disorder of protein aggregation, comprising: (i) administering said test compound to a plurality of transgenic (a) a first transgene comprising a nucleic acid encoding a human protein that aggregates and a nucleic acid encoding a first fluorescent protein, operably linked to a and (b) a second transgene comprising a nucleic acid encoding a marker protein, operably linked to a (ii) determining the difference in the amount of human protein that aggregates, in the presence of the test compound as compared to in the absence of the test compound, in the plurality of (iii) calculating the number of (iv) determining, by dividing the results of step (ii) with the results of step (iii), the difference in the amount of human protein that aggregates, per worm, resulting from the administration of the test compound; wherein, if administration of the test compound results in a decrease in the amount of human protein that aggregates per worm, then the test compound is identified as a candidate compound that may be therapeutically effective in a disorder of protein aggregation.